FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Ascend Laboratories Rasagiline Mesylate Tablets 1 mg Recall

Rasagiline Mesylate Tablets 1 mg

Ascend Laboratories, LLC · Parsippany, NJ

Risk level
Class II
Reported by FDA
Jan 25, 2023
Recall ID
D-0159-2023
Check your lot numberHow we source this data

Summary

Ascend Laboratories recalled Rasagiline Mesylate Tablets 1 mg starting Dec 28, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0159-2023 on Jan 25, 2023. Reason: Presence of Foreign Substance- A complaint was received of black spots/shiny metallic speck on the tablets. Status: Terminated.

Why it was recalled

Presence of Foreign Substance- A complaint was received of black spots/shiny metallic speck on the tablets.

Product description

Rasagiline Mesylate Tablets 1 mg; 30 tablets in HDPE bottle; Rx only; NDC 67877-260-30; Manufactured by Alkem Laboratories Ltd., India; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054

Lot numbers, UPCs & expiration codes

Lot # 22140903. Exp. Dec. 2024

Where it was sold

Customers in 19 states: CA, FL, GA, IL, KY, LA, MI, MN, MS, NC, NJ, NY, OH, PA, RI, TN, TX, WA, WI; Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0159-2023
Classification
Class II
Status
Terminated
Recall initiated
Dec 28, 2022
FDA report date
Jan 25, 2023
Quantity
12192 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Ascend Laboratories, LLC

Original FDA data

Every field from FDA enforcement report D-0159-2023, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
91385
Address
339 Jefferson Rd Ste 101
Code information
Lot # 22140903. Exp. Dec. 2024
Postal code
07054-3707
Report date
Jan 25, 2023
Product type
Drugs
Recall number
D-0159-2023
Classification
Class II
Recalling firm
Ascend Laboratories, LLC
Product quantity
12192 bottles
Termination date
Aug 15, 2024
Reason for recall
Presence of Foreign Substance- A complaint was received of black spots/shiny metallic speck on the tablets.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Rasagiline Mesylate Tablets 1 mg; 30 tablets in HDPE bottle; Rx only; NDC 67877-260-30; Manufactured by Alkem Laboratories Ltd., India; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054
Distribution pattern
Customers in 19 states: CA, FL, GA, IL, KY, LA, MI, MN, MS, NC, NJ, NY, OH, PA, RI, TN, TX, WA, WI; Puerto Rico
Recall initiation date
Dec 28, 2022
Initial firm notification
E-Mail
Center classification date
Jan 16, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0159-2023, published Jan 25, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls